Skip to main content

Table 4 Kaplan–Meier survival curves for progression-free survival

From: Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

  Mean by months % End of study by months Log-rank
χ2 p value
Groups
 Group A 23.0 66.7 2.622 0.105
 Group B 39.0 92.3